Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Running

LIGHTHEART Surgical optogenetic bioprinting of engineered cardiac muscle

Coordinator
Ruprecht-Karls-Universitaet Heidelberg, Germany
Runs
1 March 2023 to 29 February 2028
Status
Running
EU funding
€1.5m
Total cost
€1.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101077419

What the project is doing

In the project's own words, from its summary on CORDIS.

Heart failure remains a leading cause of mortality worldwide taking an estimate of 16 million lives each year. Cardiac tissue engineering solutions that can improve the quality of life of those with advanced heart disease have proved challenging so far. Bioprinting is an exciting technology that holds promise to fabricate tissues and organs. Lab-grown engineered cardiac muscle requires at least four weeks to maturate in a bioreactor.

In LIGHTHEART, an off-the-shelf solution will be developed for treating injured myocardium in vivo. An unconventional combination of bioprinting and optogenetics will be used to surgically fabricate engineered cardiac muscle directly at the patient’s heart. A surgical bioprinting tool will be constructed to achieve vascularization and cellular architectures as that observed in native cardiac muscle. Induced pluripotent stem cell-derived cardiac cells will be the basis of the bioinspired biomaterial-free ink that will be printed.

Optogenetic expression of different light-sensitive proteins at the cell surfaces will be the sole trigger of cellular assembly, thus omitting the need to embed cells in hydrogels or printing in a supporting bath. Surgical optogenetic bioprinting will be first tested ex vivo using a silicone human phantom with a mimicking beating heart, and later in vivo in a large animal model in accordance with the 3R principles. LIGHTHEART opens up new horizons in the way heart failure can be clinically treated and brings hope to patients who are desperately waiting for a heart transplantation.

The disruptive nature of LIGHTHEART will unite engineers, surgeons and scientists to change the future of transplantation medicine with modular bottom-up technologies that allow for in vivo tissue and organ restoration or replacement directly at the operating theatre.

Topics

Who is involved

OrganisationCityCountryRole
Ruprecht-Karls-Universitaet HeidelbergHeidelbergGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI